{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:35Z","timestamp":1786982675311,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T00:00:00Z","timestamp":1640736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s13555-021-00666-x","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T09:02:43Z","timestamp":1640854963000},"page":"481-494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Ixekizumab 80\u00a0mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03942042","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Akimichi","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoe","family":"Torisu-Itakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,29]]},"reference":[{"issue":"4","key":"666_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis\u2013epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314\u201320.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"666_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199503023320907","volume":"332","author":"MW Greaves","year":"1995","unstructured":"Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med. 1995;332(9):581\u20138.","journal-title":"N Engl J Med"},{"key":"666_CR3","unstructured":"International Federation of Psoriasis Associations (IFPA). Profile of psoriasis. 2013. Available at: http:\/\/www.ifpa-pso.org\/web\/page.aspx?refid=42. Accessed 16 June 2014"},{"key":"666_CR4","doi-asserted-by":"crossref","unstructured":"Tang B, Annunziata K, Di Bonaventura M. Burden of psoriasis in developing and developed countries. In: International society for pharmacoeconomics and outcomes research 19th annual international meeting research abstracts. 2014; 17(3)","DOI":"10.1016\/j.jval.2014.03.1682"},{"issue":"3","key":"666_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/1346-8138.14105","volume":"45","author":"T Ito","year":"2018","unstructured":"Ito T, Takahashi H, Kawada A, Iizuka H, Nakagawa H. Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research. J Dermatol. 2018;45(3):293\u2013301.","journal-title":"J Dermatol"},{"key":"666_CR6","first-page":"131","volume":"6","author":"KE Benjegerdes","year":"2016","unstructured":"Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131\u201344.","journal-title":"Psoriasis (Auckl)"},{"key":"666_CR7","unstructured":"Komine M, Iwatsuki K, Kurosawa M, Muto M. Pustular psoriasis diagnosis guidance. Clinical practice guideline for rare and intractable skin diseases (revised edition). 2014:38\u201358."},{"key":"666_CR8","first-page":"93","volume":"6","author":"RK Singh","year":"2016","unstructured":"Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:93\u2013104.","journal-title":"Psoriasis (Auckl)"},{"issue":"4","key":"666_CR9","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2009.05.048","volume":"62","author":"M Rosenbach","year":"2010","unstructured":"Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"666_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","volume":"304","author":"SB Yilmaz","year":"2012","unstructured":"Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304(6):465\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"666_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamadermatol.2015.2","volume":"151","author":"AP Moy","year":"2015","unstructured":"Moy AP, Murali M, Kroshinsky D, Duncan LM, Nazarian RM. Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis. JAMA Dermatol. 2015;151(7):753\u201360.","journal-title":"JAMA Dermatol"},{"key":"666_CR12","unstructured":"Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) approval of Ixekizumab. https:\/\/www.pmda.go.jp\/files\/000224346.pdf. Accessed 16 July 2021."},{"key":"666_CR13","unstructured":"Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) approval of Ixekizumab. https:\/\/www.pmda.go.jp\/files\/000235288.pdf. Accesse 16 July 2021."},{"key":"666_CR14","doi-asserted-by":"crossref","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: Results from a 52-week, open-label study. British Journal of Dermatology. 2016;176.","DOI":"10.1111\/bjd.14702"},{"key":"666_CR15","unstructured":"Japanese Dermatological Association. Japanese Dermatological Guidelines for General Pustular Psoriasis (2014 edition). Available on nouhouseikansenguideline.pdf (dermatol.or.jp). Accessed 22 Oct 2021."},{"issue":"1","key":"666_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjd.14464","volume":"175","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Naegeli AN, Edson-Heredia E, Lin CY, Gaich C, Nika\u00ef E, et al. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(1):157\u201362.","journal-title":"Br J Dermatol"},{"issue":"5","key":"666_CR17","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The dermatology life quality index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997\u20131035.","journal-title":"Br J Dermatol"},{"issue":"4","key":"666_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423\u201341.","journal-title":"Drugs"},{"issue":"Suppl 3","key":"666_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jdv.12162","volume":"27","author":"MA Richard","year":"2013","unstructured":"Richard MA, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, et al. Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):2\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"666_CR20","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/jdv.12773","volume":"29","author":"H Saeki","year":"2015","unstructured":"Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"666_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s13555-020-00441-4","volume":"10","author":"M Honma","year":"2020","unstructured":"Honma M, Cai Z, Burge R, Zhu B, Yotsukura S, Torisu-Itakura H. Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of japanese patients with moderate-to-severe psoriasis treated with ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb). 2020;10(6):1397\u2013404.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T22:15:17Z","timestamp":1645049717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,29]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00666-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,29]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}